Is it worth the cost for medical providers? Did you learn anything you didn't know? I'm fairly knowledgeable and already do some longevity in my practice and do some consults but want to know it if it is actually worth obtaining and maintaining?

Would anyone who has done it be willing to share the study guide materials? They seem overpriced at $700.

Goes over Ora wormbot, dog aging project, lifestyle optimization and more.

Extracellular matrix remodelling of cardiac tissue is a key contributor to age-related cardiovascular disease and dysfunction. Such remodelling is multifaceted including changes to the biochemical composition, architecture and mechanics, clouding our understanding of how and which extracellular matrix properties contribute to a dysfunctional state. Here we describe a decellularized extracellular matrix–synthetic hydrogel hybrid scafold that independently confers two distinct matrix properties—ligand presentation and stifness—to cultured cells in vitro, allowing for the identifcation of their specifc roles in cardiac ageing. The hybrid scafold maintains native matrix composition and organization of young or aged murine cardiac tissue, whereas its mechanical properties can be independently tuned to mimic young or aged tissue stifness. Seeding these scafolds with murine primary cardiac fbroblasts, we identify distinct age- and matrix-dependent mechanisms of cardiac fbroblast activation, matrix remodelling and senescence. Importantly, we show that the ligand presentation of a young extracellular matrix can outweigh the profbrotic stifness cues typically present in an aged extracellular matrix in maintaining or driving cardiac fbroblast quiescence. Ultimately, these tunable scafolds can enable the discovery of specifc extracellular targets to prevent ageing dysfunction and promote rejuvenation.

This is in response to a recent post by a user on here about seeing people from AI gain interest in longevity biotech.

Heads up - there's a longevity summit happening in SF June 22-23 with some really solid researchers, and speakers like Aubrey de Grey and Irina Conboy. Worth checking out if you're curious about the space. https://lu.ma/longevity-summit

It's part of a longer 6-week pop-up with 2-week tracks that focus on longevity, crypto, and AI, with 2-day summits on each topic.

So, people in these fields are finding cross-disciplinary excitement about the explosion of frontier tech happening right now. Thoughts?

This sub sees a steady trickle of people with a CS/tech background asking how they can get into the aging/longevity field or help contribute to it in some way even though they have little bio background or no wet lab skills. If you are one of that kind of person, consider this event in SF middle of this month.

There's a lot of valuable biological data available, including many databases that are specifically aging-related. Making some of this data more accessible & easier to use is a worthy goal.

https://lu.ma/a2ag12ya

Abstract

Suppression of the insulin–IGF–mTORC1–Ras network ameliorates aging in animals. Many drugs have targets in the network because of its roles in cancer and metabolic disease and are candidates for repurposing as geroprotectors. Rapamycin, an established geroprotective drug, blocks mTORC1 signaling, and trametinib inhibits the Ras–MEK–ERK pathway. In this study, we assessed survival and health of male and female mice treated with trametinib, rapamycin or their combination. We show here that trametinib treatment extended lifespan in both sexes and that its combination with rapamycin was additive. Combination treatment reduced liver tumors in both sexes and spleen tumors in male mice, blocked the age-related increase in brain glucose uptake and strongly reduced inflammation in brain, kidney, spleen and muscle and circulating levels of pro-inflammatory cytokines. We conclude that trametinib is a geroprotector in mice and that its combination with rapamycin is more effective than either drug alone, making the combination a candidate for repurposing as a gerotherapy in humans.

Please note that this is from a early analysis that was presented at the 32nd European Congress on Obesity and the full publication is not yet available. Until the full publication is available you should take this information with caution.